Drug-induced liver injury in cancer patients

This review includes information about epidemiological data, development feature, phenotypes, principles of classification, diagnosis, and prognosis for drug-induced liver injury (DILI). Actual clinical recommendations regarding management of the DILI arising in the chemotherapy of cancer discussed. Drugs that can influence on individual pathogenetic mechanisms of growth and symptoms DILI are considered. Clinical studies for the prophylaxis and treatment of DILI associated with anticancer chemotherapy analyzed in detail. The prevention and treatment regimens for DILI in patients receiving chemotherapy and immunotherapy various localizations of cancer given both in research and in practical recommendations.

1. Larionova V.B., Gromova E.G., Snegovoy A.V. Clinical guidelines for the correction of hepatotoxicity induced by antitumor chemotherapy. M., 2014. Available at: http://www.oncology.ru/association/clinical-guidelines/2014/09.pdf. (In Russ.).

2. Bahirwani R., Reddy K.R. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014;34(2):162–71. DOI: 10.1055/s-0034-1375957.

3. Azad A., Chang P., Devuni D. et al. Real world experience of drug induced liver injury in patients undergoing chemotherapy. J Clin Gastroenterol Hepatol 2018;2(3):18. DOI: 10.21767/2575-7733.1000047.

4. Andrade R.J., Aithal G.P., Björnsson E.S. et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 2019;70(6):1222–61. DOI: 10.1016/j.jhep.2019.02.014.

5. Chalasani N.P., Hayashi P.H., Bonkovsky H.L. et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109(7):950–66. DOI: 10.1038/ajg.2014.131.

6. Ivashkin V.T., Baranovsky A.Yu., Raikhelson K.L. et al. Drug-induced liver injuries (clinical guidelines for physicians). Rossijskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019;29(1):85–115. (In Russ.)].

7. Lazebnik L.B., Golovanova E.V., Hlynova O.V. et al. Medicinal liver damage in adults. Eksperimental’naya i kinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2020;174(2):29–54. (In Russ.).

8. Practical recommendations for drugtreatment of malignant tumors. Practical recommendations for maintenance therapy in oncology. Zlokachestvennye opukholi = Malignant Tumours 2015;(4s):1–456. (In Russ.).

9. Clinical guidelines protocols for maintenance therapy in oncology. The Society of Supportive Care in Oncology (RASSC). Ed.: M.I. Davydov. 2nd ed., rev. Moscow: ABV-press, 2018. 224 p. (In Russ.).

10. Tkachenko P.E., Ivashkin V.T., Mayevskaya M.V. Clinical guidelines for the correction of hepatotoxicity induced by antitumor therapy. Malignant tumors: Practical guidelines RUSSCO 2019;9(3s2):595–608. (In Russ.)].

11. Ricart A.D. Drug-induced liver injury in Oncology. Ann Oncol 2017;28(8):2013–20. DOI: 10.1093/annonc/mdx158.

12. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008;14(44):6774–85. DOI: 10.3748/wjg.14.6774.

13. Reporting adverse drug reactions: definitions of terms and criteria for their use. Geneva: CIOMS, 1999. 146 p.

14. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89(6):806–5. DOI: 10.1038/clpt.2011.58.15. https://www.cancer.gov/about-cancer/causes-prevention.

15. Burt A.D., Ferrell L.D., Hubscher S. et al. MacSween’s Pathology of the Liver, 6th edn. Edinburgh: Churchill Livingstone (Elsevier), 2012. Pp. 645–760.

16. Ortega-Alonso A., Stephens C., Lucena M.I. et al. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci 2016;17(5):714. DOI: 10.3390/ijms17050714.

17. Danan G., Benichou C.J. Causality assessment of adverse reactions to drugs – I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46(11):1323–30. DOI: 10.1016/0895-4356(93)90101-6.

18. Danan G., Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2015;17(1):14. DOI: 10.3390/ijms17010014.

19. Drug-Induced Liver Injury Network. Available at: http://www.dilin.org.

20. LiverTox. Clinical and research information on drug-induced liver injury. Available at: https://livertox.nih.gov.

21. Zimmerman H.J. Drug-induced liver disease. In: Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. N.Y.: Appleton-Century- Crofts, 1978. Pp. 351–353.

22. Andrade R.J., Lucena M.I., Fernández M.C. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129(2):512–21. DOI: 10.1016/j.gastro.2005.05.006.

23. Lo Re V. 3rd, Haynes K., Forde K.A. et al. Risk of acute liver failure in patients with drug-induced liver injury: evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol 2015;13(13): 2360–8. DOI: 10.1016/j.cgh.2015.06.020.

24. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol 2016;10(4):517–36. DOI: 10.1586/17474124.2016.1127756.

25. Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin Proc 2014;89(1):95–106. DOI: 10.1016/j.mayocp.2013.09.016.

26. Woodhead J.L., Howell B.A., Yang Y. et al. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 2012;342(2):529–40. DOI: 10.1124/jpet.112.192930.

27. Cancer Therapy Evaluating Program. Common Terminology Criteria for Adverse Events. Ver.3.0 (CTCAE). Available at: http://ctep.cancer.gov.

28. Eroglu N., Erduran E., Reis G.P., Bahadır A. Therapeutic effect of Nacetylcysteine on chemotherapy-induced liver injury. Ir J Med Sci 2020. DOI: 10.1007/s11845-020-02219-1.

29. Shea B., Swinden M.V., Ghogomu E.T. et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 2014;41(6):1049–60. DOI: 10.3899/jrheum.130738.

30. Björnsson E.S. Gunnarsson B.I., Gröndal G. et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 2015;13(3):602–8. DOI: 10.1016/j.cgh.2014.07.062.

31. Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol 2012;57(5):1097–109. DOI: 10.1016/j.jhep.2012.04.041.

32. Saigal S., Kapoor D., Roy D.S. Ademetionine in patients with liver disease: a review. Int J Res Med Sci 2019;7(6):2482–93. DOI: 10.18203/2320-6012.ijrms20192550.

33. Raikhelson K.L., Kondrashina E.A. Аdеmethionine in the treatment of fatigue in liver diseases: a systematic review. Therapeutic Archive 2019;91(2):8–142. (In Russ.).

34. Vincenzi B., Santini D., Frezza A.M. et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf 2011;10(3):345–9. DOI: 10.1517/14740338.2011.562888.

35. Vincenzi B., Daniele S., Frezza A.M. et al. The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatinbased regimen. Support Care Cancer 2012;20(1):135–9. DOI: 10.1007/s00520-010-1078-4.

36. Santini D., Vincenzi B., Massacesi C. et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res 2003;23(6D):5173–9.

37. Snegovoi A.V., Larionova V.B., Zeynalova P.A. et al. Final results prospective, multicenter program P12-717 (same application in chronic liver disease, conditionality of drug-induced liver injury due to chemotherapy). Vestnik RONTS im. N.N. Blokhina RAMN = Journal of N.N. Blokhin Russian Cancer Research Center 2016;27(2):143–56. (In Russ.).

38. Li T.W., Peng H., Yang H. et al. SAdenosylmethionine and methylthioadenosine inhibit β-catenin signaling by multiple mechanisms in liver and colon cancer. Mol Pharmacol 2015;87(1):77–86. DOI: 10.1124/mol.114.095679.

39. Snegovoi A.V., Gromova E.G., Larionova V.B. Practical recommendations for the correction of hepatotoxicity induced by anti-tumor chemotherapy. Zlokachestvennye opukholi = Malignant Tumours 2015;4(special issue):358–68. (In Russ.).

40. Konopatskova O.M., Averyanova S.V. Use of Remaxol in the polychemotherapy of patients with breast cancer. Onkologiya. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology 2015;4(6):35–7. (In Russ.).

41. Konopatskova O.M., Averyanova S.V. Adjunct therapy during combination chemotherapy for colorectal cancer. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2016;5(1):42–6. (In Russ.).

42. Li M., Liu G.T. Inhibition of Fas/FasL mRNA expression and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. World J Gastroenterol 2004;10(12):1775–9. DOI: 10.3748/wjg.v10.i12.1775.

43. Liu G.T., Li Y., Wei H.L. et al. Toxicity of novel anti-hepatitis drug bicyclol: a preclinical study. World J Gastroenterol 2005;11(5):665–71. DOI: 10.3748/wjg.v11.i5.665.

44. Bao X., Liu G. Bicyclol protects HepG2 cells against D-galactosamine-induced apoptosis through inducing heat shock protein 27 and mitochondria associated pathway. Acta Pharmacol Sin 2010;31(2):219–26. DOI: 10.1038/aps.2009.194.

45. Wang Y., Nie H., Zhao X. et al. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer 2016;16(1):742. DOI: 10.1186/s12885-016-2767-2.

46. Li X., Zhou J., Chen S. et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res 2014;42(4):906–14. DOI: 10.1177/0300060514527058.

47. Huang Y.S. The Therapeutic efficacy of ursodeoxycholic acid (UDCA) in drug-induced liver injury: results of a randomized controlled trial. Gastroenterology 2010;138(5):809. DOI: 10.1016/S0016-5085(10)63727-4.

48. Wree A., Dechêne A., Herzer K. et al. Steroid and ursodesoxycholic Acid combination therapy in severe druginduced liver injury. Digestion 2011;84(1):54–9. DOI: 10.1159/000322298.

49. Alyeva A.A., Nikitin I.G., Arkhipov A.V. Supporting therapy of acute drug-induced liver damage during chemotherapy in patients with breast cancer. Lechebnoe delo = Medicine 2018;2:74–85. (In Russ.).

50. Gurevich K.G. Possibilities of the use of Essentiale in druginduced liver injuries. Farmateka = Farmateka 007;2:46–8. (In Russ.).

51. Kazyulin A.N., Vel’sher L.Z., Koroleva I.A. Opportunities for overcoming hepatotoxicity in the combined and complex treatment of breast cancer. Effectivnaya farmakoterapiya. Gastroenterologiya = Effective Pharmacotherapy. Gastroenterology 2011;3:66–72. (In Russ.).

52. Kobys’ V.L., Konovalenko V.F. Role ofhepatoprotectors in optimizing high-dose methotrexat chemotherapy of osteogenic sarcoma in children. Onkologiya = Oncology 2008;10(3):359–61. (In Russ.).

53. Yu Y.C., Mao Y.M., Chen C.W. et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017;11(3):221–41. DOI: 10.1007/s12072-017-9793-2.

54. Zhu X.X., Ding Y.H., Wu Y. et al. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol 2016;9(10):1323–30. DOI: 10.1080/17512433.2016.1208563.